GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Financial Strength

Guardion Health Sciences (Guardion Health Sciences) Financial Strength : 7 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Financial Strength?

Guardion Health Sciences has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Guardion Health Sciences has no long-term debt (1). Guardion Health Sciences's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.00. As of today, Guardion Health Sciences's Altman Z-Score is -11.58.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Competitive Comparison of Guardion Health Sciences's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Financial Strength distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Financial Strength falls into.



Guardion Health Sciences Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Guardion Health Sciences's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-1.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Guardion Health Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is

Guardion Health Sciences had no long-term debt (1).

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Guardion Health Sciences Inc has no debt.

2. Debt to revenue ratio. The lower, the better.

Guardion Health Sciences's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 12
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Guardion Health Sciences has a Z-score of -11.58, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -11.58 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardion Health Sciences  (NAS:GHSI) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Guardion Health Sciences has the Financial Strength Rank of 7.


Guardion Health Sciences Financial Strength Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences (Guardion Health Sciences) Business Description

Traded in Other Exchanges
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.
Executives
Katharine Joan Cox officer: Chief Accounting Officer 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall officer: CEO & President 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff 10 percent owner 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff other: See Footnote 1 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs director 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes director, officer: Chief Executive Officer 2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano director 131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin officer: Chief Accounting Officer 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan officer: Chief Commercial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans director, officer: Chief Scientific Officer 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans 10 percent owner 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth officer: General Counsel and Secretary 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten director 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Guardion Health Sciences (Guardion Health Sciences) Headlines

From GuruFocus